439 related articles for article (PubMed ID: 32864784)
61. Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19.
Momtazi-Borojeni AA; Banach M; Reiner Ž; Pirro M; Bianconi V; Al-Rasadi K; Sahebkar A
Angiology; 2021 Feb; 72(2):122-130. PubMed ID: 32864982
[TBL] [Abstract][Full Text] [Related]
62. Androgens, the kidney, and COVID-19: an opportunity for translational research.
Yanes Cardozo LL; Rezq S; Pruett JE; Romero DG
Am J Physiol Renal Physiol; 2021 Feb; 320(2):F243-F248. PubMed ID: 33464168
[TBL] [Abstract][Full Text] [Related]
63. The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19.
Shah H; Khan MSH; Dhurandhar NV; Hegde V
Acta Diabetol; 2021 Jul; 58(7):831-843. PubMed ID: 33587177
[TBL] [Abstract][Full Text] [Related]
64. Focus on Receptors for Coronaviruses with Special Reference to Angiotensin- Converting Enzyme 2 as a Potential Drug Target - A Perspective.
Magrone T; Magrone M; Jirillo E
Endocr Metab Immune Disord Drug Targets; 2020; 20(6):807-811. PubMed ID: 32338224
[No Abstract] [Full Text] [Related]
65. COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?
Del Turco S; Vianello A; Ragusa R; Caselli C; Basta G
Thromb Res; 2020 Dec; 196():143-151. PubMed ID: 32871306
[TBL] [Abstract][Full Text] [Related]
66. Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19?
Montanari M; Canonico B; Nordi E; Vandini D; Barocci S; Benedetti S; Carlotti E; Zamai L
Adv Biol Regul; 2021 Aug; 81():100820. PubMed ID: 34419773
[TBL] [Abstract][Full Text] [Related]
67. Susceptibility of livestock and companion animals to COVID-19.
Sreenivasan CC; Thomas M; Wang D; Li F
J Med Virol; 2021 Mar; 93(3):1351-1360. PubMed ID: 33090532
[TBL] [Abstract][Full Text] [Related]
68. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19.
Rothlin RP; Vetulli HM; Duarte M; Pelorosso FG
Drug Dev Res; 2020 Nov; 81(7):768-770. PubMed ID: 32356926
[TBL] [Abstract][Full Text] [Related]
69. Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection.
Festa M; Sansone C; Brunet C; Crocetta F; Di Paola L; Lombardo M; Bruno A; Noonan DM; Albini A
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171852
[TBL] [Abstract][Full Text] [Related]
70. SARS-CoV-2 effects on the renin-angiotensin-aldosterone system, therapeutic implications.
Ye Q; Lai EY; Luft FC; Persson PB; Mao J
Acta Physiol (Oxf); 2021 Apr; 231(4):e13608. PubMed ID: 33350096
[No Abstract] [Full Text] [Related]
71. ACE2 as a Potential Target for Management of Novel Coronavirus (nCoV- 2019).
Foroozanfar E; Forouzanfar M; Farkhondeh T; Samarghandian S; Forouzanfar F
Curr Drug Discov Technol; 2021; 18(6):e130921189567. PubMed ID: 33371835
[TBL] [Abstract][Full Text] [Related]
72. COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network.
Kario K; Morisawa Y; Sukonthasarn A; Turana Y; Chia YC; Park S; Wang TD; Chen CH; Tay JC; Li Y; Wang JG;
J Clin Hypertens (Greenwich); 2020 Jul; 22(7):1109-1119. PubMed ID: 32643874
[TBL] [Abstract][Full Text] [Related]
73. Covid-19 pandemic: Perspectives on management.
Gathiram P; Moodley J; Khaliq OP
J Reprod Immunol; 2021 Aug; 146():103344. PubMed ID: 34146892
[TBL] [Abstract][Full Text] [Related]
74. Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19.
de Barcelos Ubaldo Martins L; Jabour LGPP; Vieira CC; Nery LCC; Dias RF; Simões E Silva AC
Curr Med Chem; 2021; 28(22):4499-4530. PubMed ID: 32881654
[TBL] [Abstract][Full Text] [Related]
75. The Renin-Angiotensin System: A Key Role in SARS-CoV-2-Induced COVID-19.
El-Arif G; Farhat A; Khazaal S; Annweiler C; Kovacic H; Wu Y; Cao Z; Fajloun Z; Khattar ZA; Sabatier JM
Molecules; 2021 Nov; 26(22):. PubMed ID: 34834033
[TBL] [Abstract][Full Text] [Related]
76. The role of angiotensin-converting enzyme 2 in the pathogenesis of COVID-19: the villain or the hero?
Klhůfek J
Acta Clin Belg; 2022 Feb; 77(1):211-218. PubMed ID: 32597377
[TBL] [Abstract][Full Text] [Related]
77. Possible Therapeutic Interventions in COVID-19 Induced ARDS by Cotinine as an ACE-2 Promoter and AT-1R Blocker.
Sharma T; Mehan S
Infect Disord Drug Targets; 2021; 21(6):e170721189261. PubMed ID: 33342421
[TBL] [Abstract][Full Text] [Related]
78. ERAP1 and ERAP2 Enzymes: A Protective Shield for RAS against COVID-19?
D'Amico S; Tempora P; Lucarini V; Melaiu O; Gaspari S; Algeri M; Fruci D
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567739
[TBL] [Abstract][Full Text] [Related]
79. Is diabetes mellitus a wrongdoer to COVID-19 severity?
Sarkar S; Das D; Borsingh Wann S; Kalita J; Manna P
Diabetes Res Clin Pract; 2021 Aug; 178():108936. PubMed ID: 34217771
[TBL] [Abstract][Full Text] [Related]
80. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up.
Tajbakhsh A; Gheibi Hayat SM; Taghizadeh H; Akbari A; Inabadi M; Savardashtaki A; Johnston TP; Sahebkar A
Expert Rev Anti Infect Ther; 2021 Mar; 19(3):345-357. PubMed ID: 32921216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
